Similarly, in an NSCLC patient harboring a KLC1-ALK rearrangement, four distinct secondary ALK mutations were identified in ctDNA at the time of progression, all potentially contributing to therapeutic failure [85]. Here, ALK is linked to non-small cell lung carcinoma.